Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease.

Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, Conrado DJ, Dexter DT, Seibyl J, Jennings D, Nicholas T, Matthews D, Xie Z, Imam S, Maguire P, Russell D, Gordon MF, Stebbins GT, Somer E, Gallagher J, Roach A, Basseches P, Grosset D, Marek K; Critical Path for Parkinson’s Consortium.

J Parkinsons Dis. 2019;9(4):825. doi: 10.3233/JPD-199003. No abstract available.

PMID:
31524182
2.

Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studies.

Smith C, Malek N, Grosset K, Cullen B, Gentleman S, Grosset DG.

J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1234-1243. doi: 10.1136/jnnp-2019-321111. Epub 2019 Aug 23. Review.

3.

Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study.

Tan MMX, Malek N, Lawton MA, Hubbard L, Pittman AM, Joseph T, Hehir J, Swallow DMA, Grosset KA, Marrinan SL, Bajaj N, Barker RA, Burn DJ, Bresner C, Foltynie T, Hardy J, Wood N, Ben-Shlomo Y, Grosset DG, Williams NM, Morris HR.

Brain. 2019 Sep 1;142(9):2828-2844. doi: 10.1093/brain/awz191.

4.

Statins and Parkinson's: A complex interaction.

Carroll CB, Wyse RKH, Grosset DG.

Mov Disord. 2019 Jul;34(7):934-935. doi: 10.1002/mds.27721. No abstract available.

PMID:
31322771
5.

The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease.

Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, Conrado DJ, Dexter DT, Seibyl J, Jennings D, Nicholas T, Matthews D, Xie Z, Imam S, Maguire P, Russell D, Gordon MF, Stebbins GT, Somer E, Gallagher J, Roach A, Basseches P, Grosset D, Marek K; Critical Path for Parkinson’s Consortium.

J Parkinsons Dis. 2019;9(3):553-563. doi: 10.3233/JPD-191648.

6.

The genetic and clinico-pathological profile of early-onset progressive supranuclear palsy.

Jabbari E, Woodside J, Tan MMX, Pavese N, Bandmann O, Ghosh BCP, Massey LA, Capps E, Warner TT, Lees AJ, Revesz T, Holton JL, Williams NM, Grosset DG, Morris HR.

Mov Disord. 2019 Sep;34(9):1307-1314. doi: 10.1002/mds.27786. Epub 2019 Jul 12.

7.

L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression.

Malek N, Kanavou S, Lawton MA, Pitz V, Grosset KA, Bajaj N, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Hardy J, Williams NM, Wood N, Morris HR, Grosset DG; PRoBaND clinical consortium.

Parkinsonism Relat Disord. 2019 Aug;65:55-61. doi: 10.1016/j.parkreldis.2019.05.022. Epub 2019 May 14.

PMID:
31105012
8.

Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and α-synuclein mechanisms.

Blauwendraat C, Heilbron K, Vallerga CL, Bandres-Ciga S, von Coelln R, Pihlstrøm L, Simón-Sánchez J, Schulte C, Sharma M, Krohn L, Siitonen A, Iwaki H, Leonard H, Noyce AJ, Tan M, Gibbs JR, Hernandez DG, Scholz SW, Jankovic J, Shulman LM, Lesage S, Corvol JC, Brice A, van Hilten JJ, Marinus J; 23andMe Research Team, Eerola-Rautio J, Tienari P, Majamaa K, Toft M, Grosset DG, Gasser T, Heutink P, Shulman JM, Wood N, Hardy J, Morris HR, Hinds DA, Gratten J, Visscher PM, Gan-Or Z, Nalls MA, Singleton AB; International Parkinson's Disease Genomics Consortium (IPDGC).

Mov Disord. 2019 Jun;34(6):866-875. doi: 10.1002/mds.27659. Epub 2019 Apr 7.

PMID:
30957308
9.

Developing and validating Parkinson's disease subtypes and their motor and cognitive progression.

Lawton M, Ben-Shlomo Y, May MT, Baig F, Barber TR, Klein JC, Swallow DMA, Malek N, Grosset KA, Bajaj N, Barker RA, Williams N, Burn DJ, Foltynie T, Morris HR, Wood NW, Grosset DG, Hu MTM.

J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1279-1287. doi: 10.1136/jnnp-2018-318337. Epub 2018 Jul 25.

10.

Possible modulation of concurrent Parkinson's disease in the management of metastatic GIST: a review of two cases.

Watson-Fargie T, Grosset DG, White J, Cowie F.

J R Coll Physicians Edinb. 2018 Sep;48(3):242-245. doi: 10.4997/JRCPE.2018.309.

PMID:
30191913
11.

Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists.

Fackrell R, Carroll CB, Grosset DG, Mohamed B, Reddy P, Parry M, Chaudhuri KR, Foltynie T.

Neurodegener Dis Manag. 2018 Oct;8(5):349-360. doi: 10.2217/nmt-2018-0020. Epub 2018 Jul 5.

12.

A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease.

Silverdale MA, Kobylecki C, Kass-Iliyya L, Martinez-Martin P, Lawton M, Cotterill S, Chaudhuri KR, Morris H, Baig F, Williams N, Hubbard L, Hu MT, Grosset DG; UK Parkinson's Pain Study Collaboration.

Parkinsonism Relat Disord. 2018 Nov;56:27-32. doi: 10.1016/j.parkreldis.2018.06.001. Epub 2018 Jun 6.

13.

Features of GBA-associated Parkinson's disease at presentation in the UK Tracking Parkinson's study.

Malek N, Weil RS, Bresner C, Lawton MA, Grosset KA, Tan M, Bajaj N, Barker RA, Burn DJ, Foltynie T, Hardy J, Wood NW, Ben-Shlomo Y, Williams NW, Grosset DG, Morris HR; PRoBaND clinical consortium.

J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):702-709. doi: 10.1136/jnnp-2017-317348. Epub 2018 Jan 29.

14.

Rare case of atypical parkinsonism: why family history is important.

Malek N, Jampana R, Grosset DG.

Scott Med J. 2017 Nov;62(4):159-162. doi: 10.1177/0036933017727966. Epub 2017 Dec 1.

PMID:
29192564
15.

Statin usage, vascular diagnosis and vascular risk factors in Parkinson's disease.

Cheng KK, Swallow DM, Grosset KA, Grosset DG.

Scott Med J. 2017 Aug;62(3):104-109. doi: 10.1177/0036933017727432. Epub 2017 Aug 24.

PMID:
28836927
16.

Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases.

Malek N, Lawton MA, Grosset KA, Bajaj N, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Hardy J, Morris HR, Williams NM, Wood N, Grosset DG; PRoBaND clinical consortium.

Parkinsonism Relat Disord. 2017 Jul;40:40-46. doi: 10.1016/j.parkreldis.2017.04.006. Epub 2017 Apr 12.

17.

Autonomic Dysfunction in Early Parkinson's Disease: Results from the United Kingdom Tracking Parkinson's Study.

Malek N, Lawton MA, Grosset KA, Bajaj N, Barker RA, Burn DJ, Foltynie T, Hardy J, Morris HR, Williams NM, Ben-Shlomo Y, Wood NW, Grosset DG; PRoBaND Clinical Consortium.

Mov Disord Clin Pract. 2016 Nov 24;4(4):509-516. doi: 10.1002/mdc3.12454. eCollection 2017 Jul-Aug.

18.

Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease.

Lawton M, Hu MT, Baig F, Ruffmann C, Barron E, Swallow DM, Malek N, Grosset KA, Bajaj N, Barker RA, Williams N, Burn DJ, Foltynie T, Morris HR, Wood NW, May MT, Grosset DG, Ben-Shlomo Y.

Parkinsonism Relat Disord. 2016 Dec;33:96-101. doi: 10.1016/j.parkreldis.2016.09.023. Epub 2016 Sep 25.

19.

Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts.

Swallow DM, Lawton MA, Grosset KA, Malek N, Klein J, Baig F, Ruffmann C, Bajaj NP, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Morris HR, Williams N, Wood NW, Hu MT, Grosset DG.

J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1183-1190. doi: 10.1136/jnnp-2016-313642. Epub 2016 Sep 26.

20.

Rare variants analysis of cutaneous malignant melanoma genes in Parkinson's disease.

Lubbe SJ, Escott-Price V, Brice A, Gasser T, Pittman AM, Bras J, Hardy J, Heutink P, Wood NM, Singleton AB, Grosset DG, Carroll CB, Law MH, Demenais F, Iles MM; Melanoma Meta-Analysis Consortium, Bishop DT, Newton-Bishop J, Williams NM, Morris HR; International Parkinson's Disease Genomics Consortium.

Neurobiol Aging. 2016 Dec;48:222.e1-222.e7. doi: 10.1016/j.neurobiolaging.2016.07.013. Epub 2016 Jul 28.

21.

Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned.

Heinzel S, Roeben B, Ben-Shlomo Y, Lerche S, Alves G, Barone P, Behnke S, Berendse HW, Bloem BR, Burn D, Dodel R, Grosset DG, Hu M, Kasten M, Krüger R, Moccia M, Mollenhauer B, Oertel W, Suenkel U, Walter U, Wirdefeldt K, Liepelt-Scarfone I, Maetzler W, Berg D.

Front Aging Neurosci. 2016 Jun 22;8:147. doi: 10.3389/fnagi.2016.00147. eCollection 2016. Review.

22.

Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease.

Malek N, Lawton MA, Swallow DM, Grosset KA, Marrinan SL, Bajaj N, Barker RA, Burn DJ, Hardy J, Morris HR, Williams NM, Wood N, Ben-Shlomo Y, Grosset DG; PRoBaND Clinical Consortium.

Mov Disord. 2016 Oct;31(10):1518-1526. doi: 10.1002/mds.26698.

23.

Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies.

Lerche S, Heinzel S, Alves GW, Barone P, Behnke S, Ben-Shlomo Y, Berendse H, Bloem BR, Burn D, Dodel R, Grosset DG, Hipp G, Hu MT, Kasten M, Krüger R, Liepelt-Scarfone I, Maetzler W, Moccia M, Mollenhauer B, Oertel W, Roeben B, Walter U, Wirdefeldt K, Berg D.

Front Aging Neurosci. 2016 May 27;8:121. doi: 10.3389/fnagi.2016.00121. eCollection 2016. No abstract available.

24.

A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.

LeWitt PA, Hauser RA, Grosset DG, Stocchi F, Saint-Hilaire MH, Ellenbogen A, Leinonen M, Hampson NB, DeFeo-Fraulini T, Freed MI, Kieburtz KD.

Mov Disord. 2016 Sep;31(9):1356-65. doi: 10.1002/mds.26611. Epub 2016 Apr 19.

PMID:
27090868
25.

Variation in Recent Onset Parkinson's Disease: Implications for Prodromal Detection.

Swallow DM, Lawton MA, Grosset KA, Malek N, Smith CR, Bajaj NP, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Hardy J, Morris HR, Williams N, Wood NW, Grosset DG; PRoBaND Clinical Consortium.

J Parkinsons Dis. 2016 Mar 19;6(2):289-300. doi: 10.3233/JPD-150741.

26.

Nonmotor symptoms in patients without evidence of dopaminergic deficit.

Swallow DM, Grosset KA, Grosset DG.

Mov Disord. 2016 Mar;31(3):429-30. doi: 10.1002/mds.26541. Epub 2016 Feb 19. Review. No abstract available.

PMID:
26891715
27.

A randomized trial of specialized versus standard neck physiotherapy in cervical dystonia.

Counsell C, Sinclair H, Fowlie J, Tyrrell E, Derry N, Meager P, Norrie J, Grosset D.

Parkinsonism Relat Disord. 2016 Feb;23:72-9. doi: 10.1016/j.parkreldis.2015.12.010. Epub 2015 Dec 18.

PMID:
26723272
28.

Olfaction in Parkin single and compound heterozygotes in a cohort of young onset Parkinson's disease patients.

Malek N, Swallow DM, Grosset KA, Lawton MA, Smith CR, Bajaj NP, Barker RA, Ben-Shlomo Y, Bresner C, Burn DJ, Foltynie T, Morris HR, Williams N, Wood NW, Grosset DG; PRoBaND Investigators.

Acta Neurol Scand. 2016 Oct;134(4):271-6. doi: 10.1111/ane.12538. Epub 2015 Dec 1.

PMID:
26626018
29.

Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease--Report of the JPND Working Group BioLoC-PD.

Lerche S, Liepelt-Scarfone I, Alves G, Barone P, Behnke S, Ben-Shlomo Y, Berendse H, Burn D, Dodel R, Grosset D, Heinzel S, Hu M, Kasten M, Krüger R, Maetzler W, Moccia M, Mollenhauer B, Oertel W, Roeben B, Sünkel U, Walter U, Wirdefeldt K, Berg D.

Neuroepidemiology. 2015;45(4):282-97. doi: 10.1159/000439221. Epub 2015 Nov 3.

30.

Tracking Parkinson's: Study Design and Baseline Patient Data.

Malek N, Swallow DM, Grosset KA, Lawton MA, Marrinan SL, Lehn AC, Bresner C, Bajaj N, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Hardy J, Morris HR, Williams NM, Wood N, Grosset DG; PRoBaND.

J Parkinsons Dis. 2015;5(4):947-59. doi: 10.3233/JPD-150662.

31.

Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease.

Stephenson D, Hu MT, Romero K, Breen K, Burn D, Ben-Shlomo Y, Bhattaram A, Isaac M, Venuto C, Kubota K, Little MA, Friend S, Lovestone S, Morris HR, Grosset D, Sutherland M, Gallacher J, Williams-Gray C, Bain LJ, Avilés E, Marek K, Toga AW, Stark Y, Forrest Gordon M, Ford S.

J Parkinsons Dis. 2015;5(3):581-94. doi: 10.3233/JPD-150570.

32.

Medication adherence in patients with Parkinson's disease.

Malek N, Grosset DG.

CNS Drugs. 2015 Jan;29(1):47-53. doi: 10.1007/s40263-014-0220-0. Review.

PMID:
25503824
33.

Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.

Grosset DG, Tyrrell EG, Grosset KA.

J Rehabil Med. 2015 Feb;47(2):183-6. doi: 10.2340/16501977-1895.

34.

How head and neck consultants manage patients' emotional distress during cancer follow-up consultations: a multilevel study.

Zhou Y, Humphris G, Ghazali N, Friderichs S, Grosset D, Rogers SN.

Eur Arch Otorhinolaryngol. 2015 Sep;272(9):2473-81. doi: 10.1007/s00405-014-3209-x. Epub 2014 Jul 31.

PMID:
25078155
35.

Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials.

O'Brien JT, Oertel WH, McKeith IG, Grosset DG, Walker Z, Tatsch K, Tolosa E, Sherwin PF, Grachev ID.

BMJ Open. 2014 Jul 3;4(7):e005122. doi: 10.1136/bmjopen-2014-005122.

36.

Safety analysis of 10 clinical trials and for 13 years after first approval of ioflupane 123I injection (DaTscan).

Grosset DG, Tatsch K, Oertel WH, Tolosa E, Bajaj N, Kupsch A, O'Brien JT, Seibyl J, Walker Z, Sherwin P, Chen C, Grachev ID.

J Nucl Med. 2014 Aug;55(8):1281-7. doi: 10.2967/jnumed.114.138032. Epub 2014 Jun 19.

37.

Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with Parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging.

Seibyl JP, Kupsch A, Booij J, Grosset DG, Costa DC, Hauser RA, Darcourt J, Bajaj N, Walker Z, Marek K, McKeith I, O'Brien JT, Tatsch K, Tolosa E, Dierckx RA, Grachev ID.

J Nucl Med. 2014 Aug;55(8):1288-96. doi: 10.2967/jnumed.114.140228. Epub 2014 Jun 12.

38.

Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review.

Malek N, Swallow D, Grosset KA, Anichtchik O, Spillantini M, Grosset DG.

Acta Neurol Scand. 2014 Aug;130(2):59-72. doi: 10.1111/ane.12247. Epub 2014 Apr 5. Review.

PMID:
24702516
39.

Baseline [(123) I]FP-CIT SPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson's disease.

Nissen T, Malek N, Grosset KA, Newman EJ, Patterson J, Hadley D, Grosset DG.

Acta Neurol Scand. 2014 Mar;129(3):204-8. doi: 10.1111/ane.12178. Epub 2013 Aug 20.

PMID:
23962145
40.

Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study.

Grosset KA, Malek N, Morgan F, Grosset DG.

J Parkinsons Dis. 2013;3(1):31-7. doi: 10.3233/JPD-120142.

PMID:
23938309
41.

Inhaled dry powder apomorphine (VR040) for 'off ' periods in Parkinson's disease: an in-clinic double-blind dose ranging study.

Grosset KA, Malek N, Morgan F, Grosset DG.

Acta Neurol Scand. 2013 Sep;128(3):166-71. doi: 10.1111/ane.12107. Epub 2013 Mar 26.

PMID:
23527823
42.

Prescription of drugs with potential adverse effects on cardiac conduction in Parkinson's disease.

Malek NM, Grosset KA, Stewart D, Macphee GJ, Grosset DG.

Parkinsonism Relat Disord. 2013 Jun;19(6):586-9. doi: 10.1016/j.parkreldis.2013.02.004. Epub 2013 Mar 20.

PMID:
23522959
43.

Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing 'off' periods in patients with established Parkinson's disease.

Grosset KA, Malek N, Morgan F, Grosset DG.

Eur J Neurol. 2013 Nov;20(11):1445-50. doi: 10.1111/ene.12091. Epub 2013 Jan 28.

PMID:
23350812
44.

Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease.

Nissen T, Newman EJ, Grosset KA, Daghem M, Pal G, Stewart M, Odin P, Macphee GJ, Grosset DG.

Scott Med J. 2012 Nov;57(4):217-20. doi: 10.1258/smj.2012.012121. Epub 2012 Sep 21.

PMID:
23002158
45.

Accuracy of subjective and objective handwriting assessment for differentiating Parkinson's disease from tremulous subjects without evidence of dopaminergic deficits (SWEDDs): an FP-CIT-validated study.

Bajaj NP, Wang L, Gontu V, Grosset DG, Bain PG.

J Neurol. 2012 Nov;259(11):2335-40. doi: 10.1007/s00415-012-6495-5. Epub 2012 Apr 25.

PMID:
22532169
46.

Investigational agents in the treatment of Parkinson's disease: focus on safinamide.

Malek NM, Grosset DG.

J Exp Pharmacol. 2012 Aug 14;4:85-90. doi: 10.2147/JEP.S34343. eCollection 2012. Review.

47.

Pathological gambling in Parkinson's disease--a review of the literature.

Djamshidian A, Cardoso F, Grosset D, Bowden-Jones H, Lees AJ.

Mov Disord. 2011 Sep;26(11):1976-84. doi: 10.1002/mds.23821. Epub 2011 Jun 9. Review.

PMID:
21661054
48.

Dopamine agonists vs levodopa in impulse control disorders.

Grosset DG, Cardoso F, Lees A.

Arch Neurol. 2011 Apr;68(4):544-5; author reply 545-6. doi: 10.1001/archneurol.2011.41. No abstract available.

PMID:
21482941
49.

[123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes.

Hauser RA, Grosset DG.

J Neuroimaging. 2012 Jul;22(3):225-30. doi: 10.1111/j.1552-6569.2011.00583.x. Epub 2011 Mar 16. Review.

PMID:
21410815
50.

Supplemental Content

Loading ...
Support Center